Rhumbline Advisers Sells 11,028 Shares of Myriad Genetics, Inc. $MYGN

Rhumbline Advisers cut its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 3.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,474 shares of the company’s stock after selling 11,028 shares during the period. Rhumbline Advisers owned about 0.30% of Myriad Genetics worth $2,470,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MYGN. GAMMA Investing LLC boosted its stake in Myriad Genetics by 520.8% during the first quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock worth $40,000 after buying an additional 3,750 shares in the last quarter. State of Wyoming boosted its stake in Myriad Genetics by 147.0% during the first quarter. State of Wyoming now owns 8,641 shares of the company’s stock worth $77,000 after buying an additional 5,143 shares in the last quarter. CWM LLC boosted its stake in Myriad Genetics by 600.2% during the first quarter. CWM LLC now owns 9,796 shares of the company’s stock worth $87,000 after buying an additional 8,397 shares in the last quarter. M.E. Allison & CO. Inc. acquired a new stake in Myriad Genetics during the first quarter worth $93,000. Finally, Baird Financial Group Inc. acquired a new stake in Myriad Genetics during the first quarter worth $105,000. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Stock Performance

Myriad Genetics stock opened at $7.50 on Wednesday. The firm has a market cap of $697.80 million, a P/E ratio of -1.75 and a beta of 1.93. The business’s fifty day moving average is $5.65 and its two-hundred day moving average is $6.41. Myriad Genetics, Inc. has a 52 week low of $3.76 and a 52 week high of $29.30.

Analyst Upgrades and Downgrades

Separately, Scotiabank downgraded shares of Myriad Genetics from a “sector outperform” rating to a “sector perform” rating and decreased their price target for the stock from $20.00 to $6.00 in a research note on Wednesday, May 21st. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.45.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.